Can Japan hold on to its ‘indispensable’ companies? - Financial Times

Last Updated: 03.07.2025 02:48

Can Japan hold on to its ‘indispensable’ companies? - Financial Times

Join FT Edit

Only $49 a year

Access to eight surprising articles a day, hand-picked by FT editors. For seamless reading, access … [+73 chars]

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Get 2 months free with an annual subscription at was $59.88now $49.